drugset
drugset / Trial / NCT02619851

A Clinical Trial to Evaluate the Safety and Efficacy of ALLO-ASC-DFU for Second Deep Degree Burn Injury Subjects

NCT02619851 ↗

Phase 2 Completed 20 enrolled Anterogen Co., Ltd.
RandomizedParallel-groupOpen-labelTreatment

Summary

This clinical trial is a Phase II controlled, parallel, open-label trial, designed to test the efficacy and safety of ALLO-ASC-DFU and conventional therapy in Deep Second-degree burn wound subjects.

Timeline

Start
2015-12-23
Primary completion
2019-07-02
Completion
2021-07-13

Drugs

EvaluationDrugModalityDoseRoute
Subject mesenchymal stem cells Cell therapy — —

Indications

No indication recorded.